Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced new data further defining the potential of mogamulizumab in the treatment of relapsed or refractory ...
Learn the correct pronunciation of the Mogamulizumab-kpkc, understand it's uses, recommended dosages, its indications, how to take, when to take, when not to take, side effects, special precautions, ...
New data from the PROCLIPI study has shown a meaningful overall survival benefit for patients with advanced cutaneous T-cell lymphoma (CTCL) treated with POTELIGEO (mogamulizumab). The findings were ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Review the side-effects of Mogamulizumab-kpkc as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority ...
Second- and third-line treatment for adults with mycosis fungoides or Sézary syndrome reimbursed by Croatia's National Health Insurance Fund (NHIF), effective as of 15 th November 2024. Bulgaria's ...
The PROCLIPI study, one of the largest studies to date in cutaneous T-cell lymphoma (CTCL), is a prospective, observational, multicentre international registry spanning 19 countries and includes over ...
(HealthDay News) — For patients with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy-tropical spastic paraparesis (HAM-TSP), treatment with the humanized anti-CCR4 monoclonal antibody ...
Second-line treatment for adults with mycosis fungoides or Sézary syndrome included in the Ministry of Health’s Drug Programme effective as of 1st July 2024. Galashiels and Marlow, United Kingdom, and ...
Human T-lymphotropic virus type 1 (HTLV-1) causes the debilitating neuroinflammatory disease HTLV-1–associated myelopathy–tropical spastic paraparesis (HAM–TSP) as well as adult T-cell ...
ATLANTA — A new investigational agent, mogamulizumab (Kyowa Kirin), holds promise as a new treatment option for cutaneous T-cell lymphoma (CTCL), according to results of a large phase 3 trial. The ...
Please provide your email address to receive an email when new articles are posted on . The combination of mogamulizumab and topical steroids conferred favorable outcomes to patients with previously ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results